Elutia (Elutia) ROCE % : -1,072.32% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Elutia ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Elutia's annualized ROCE % for the quarter that ended in Dec. 2023 was -1,072.32%.

Elutia ROCE % Historical Data

The historical data trend for Elutia's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elutia ROCE % Chart

Elutia Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-21.44

-39.18

-40.03

-92.08

-266.18

Elutia Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-77.57	-113.01	-253.52	-292.51	-1,072.32

Elutia ROCE % Calculation

Elutia's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-35.425	/	( ( (68.841 - 42.615)	+	(43.428 - 43.037) )	/ 2 )
	=	-35.425	/	( (26.226	+	0.391)	/ 2 )
	=	-35.425	/	13.3085
	=	-266.18 %

Elutia's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-54.876	/	( ( (54.58 - 44.736)	+	(43.428 - 43.037) )	/ 2 )
	=	-54.876	/	( ( 9.844	+	0.391 )	/ 2 )
	=	-54.876	/	5.1175
	=	-1,072.32 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Elutia (NAS:ELUT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Elutia ROCE % Related Terms

Thank you for viewing the detailed overview of Elutia's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Elutia (Elutia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elutia Inc (NAS:ELUT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

12510 Prosperity Drive, Suite 370, Silver Spring, MD, USA, 20904

Website

https://www.aziyo.com

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health, Orthobiologics, and Cardiovascular. It generates maximum revenue from the Orthobiologics segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Executives

Elutia Pipe Investment, Lp	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Birchview Fund Llc	10 percent owner	688 PINE STREET, BURLINGTON VT 05401
Thomas Englese	officer: Chief Commercial Officer	C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRING MD 20904
David Colpman	director	452 FIFTH AVENUE, NEW YORK NY 10018
Brigid Makes	director	20245 SW 95TH AVENUE, TUALATIN OR 97062
Matthew Ferguson	officer: Chief Financial Officer	C/O FOXHOLLOW TECHNOLOGIES, INC., 740 BAY ROAD, REDWOOD CITY CA 94063
Highcape Partners Gp Ii, Llc	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Gp Ii, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Qp Ii, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Ii, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Capital, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Michelle Leroux Williams	officer: Chief Scientific Officer	C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRINT MD 20904
Matthew Strobeck	10 percent owner	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Birchview Capital, Lp	10 percent owner	688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON VT 05401
Peter G Edwards	officer: GENERAL COUNSEL	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015